Corneal epithelial changes in a patient treated with belantamab mafodotin.

IF 1 Q4 OPHTHALMOLOGY Taiwan Journal of Ophthalmology Pub Date : 2023-08-11 eCollection Date: 2023-07-01 DOI:10.4103/tjo.TJO-D-22-00171
Leandro Inferrera, Rosa Giglio, Daniele Tognetto
{"title":"Corneal epithelial changes in a patient treated with belantamab mafodotin.","authors":"Leandro Inferrera, Rosa Giglio, Daniele Tognetto","doi":"10.4103/tjo.TJO-D-22-00171","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of the study is to report a case of corneal epithelial changes in a patient with refractory multiple myeloma (MM) who was treated with belantamab mafodotin (BM). A 55-year-old man diagnosed with refractory MM was referred to our hospital for treatment with BM, an antibody-drug conjugate targeting B-cell maturation antigen. After 33 days of treatment, the patient experienced a bilateral reduction in visual acuity (VA), along with dry eye symptoms such as itchy eyes and a sensation of having a foreign body. Slit-lamp examination revealed the presence of diffuse microcystic epithelial changes throughout the cornea. BM treatment was discontinued by the oncologist. Sixty days after stopping belantamab, VA gradually improved and the microcystic epithelial alterations progressively diminished. Ninety days after discontinuation of therapy, only a few microcystic epithelial alterations remained, and the patient had 20/20 VA in both eyes. While BM is an effective therapy for refractory MM, corneal epithelial changes are among the most common side effects of this treatment. Close collaboration between ophthalmologists and oncologists is crucial for assessing ocular adverse effects and tailoring treatment accordingly.</p>","PeriodicalId":44978,"journal":{"name":"Taiwan Journal of Ophthalmology","volume":"13 1","pages":"380-383"},"PeriodicalIF":1.0000,"publicationDate":"2023-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10712739/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Taiwan Journal of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/tjo.TJO-D-22-00171","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The aim of the study is to report a case of corneal epithelial changes in a patient with refractory multiple myeloma (MM) who was treated with belantamab mafodotin (BM). A 55-year-old man diagnosed with refractory MM was referred to our hospital for treatment with BM, an antibody-drug conjugate targeting B-cell maturation antigen. After 33 days of treatment, the patient experienced a bilateral reduction in visual acuity (VA), along with dry eye symptoms such as itchy eyes and a sensation of having a foreign body. Slit-lamp examination revealed the presence of diffuse microcystic epithelial changes throughout the cornea. BM treatment was discontinued by the oncologist. Sixty days after stopping belantamab, VA gradually improved and the microcystic epithelial alterations progressively diminished. Ninety days after discontinuation of therapy, only a few microcystic epithelial alterations remained, and the patient had 20/20 VA in both eyes. While BM is an effective therapy for refractory MM, corneal epithelial changes are among the most common side effects of this treatment. Close collaboration between ophthalmologists and oncologists is crucial for assessing ocular adverse effects and tailoring treatment accordingly.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
贝兰他单抗-马福多汀治疗患者角膜上皮的变化
该研究的目的是报告一例难治性多发性骨髓瘤(MM)患者角膜上皮改变,该患者接受贝兰他单抗(BM)治疗。一名55岁男性诊断为难治性MM转介到我院治疗BM,靶向b细胞成熟抗原的抗体-药物偶联物。经过33天的治疗,患者出现了双侧视力下降(VA),同时出现了眼睛发痒和异物感等干眼症状。裂隙灯检查显示整个角膜存在弥漫性微囊性上皮改变。肿瘤学家停止了BM治疗。停用贝兰他单抗60天后,VA逐渐改善,微囊性上皮改变逐渐减少。停药90天后,仅保留少量微囊性上皮改变,患者双眼VA为20/20。虽然BM是难治性MM的有效治疗方法,但角膜上皮改变是这种治疗最常见的副作用之一。眼科医生和肿瘤学家之间的密切合作对于评估眼部不良反应和相应地定制治疗至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.80
自引率
9.10%
发文量
68
审稿时长
19 weeks
期刊最新文献
Advancing glaucoma care with big data and artificial intelligence innovations. Application of artificial intelligence in glaucoma care: An updated review. Artificial intelligence and big data integration in anterior segment imaging for glaucoma. Big data and electronic health records for glaucoma research. Big data for imaging assessment in glaucoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1